ISTA Pharmaceuticals Announces Phase 3 Results for PROLENSA(TM) Eye Drops for Treatment of Pain and Inflammation After Cataract Surgery
October 18, 2011
Last week, ISTA Pharmaceuticals announced statistically significant results from the company’s Phase 3 clinical program for PROLENSA(TM) (bromfenac ophthalmic solution).
PROLENSA is a low concentration of bromfenac in a modified ophthalmic solution developed to treat pain and inflammation associated with cataract surgery. In both Phase 3 studies, PROLENSA was statistically significantly better than placebo and met the primary efficacy endpoint of absence of ocular inflammation 14 days following surgery and the secondary efficacy endpoint of elimination of ocular pain one day post-surgery. There were no serious drug-related ocular or systemic adverse events, and PROLENSA’s safety profile was found to be consistent with ISTA’s currently marketed topical non-steroidal anti-inflammatory (NSAID) compound, BROMDAY(TM) (bromfenac ophthalmic solution) 0.09%.
Click here for the full release.
You might also enjoy...
- ISTA Pharmaceuticals Announces Positive Results for Xibrom
- ISTA Pharmaceuticals Reports Results of Studies of REMURA(TM) Eye Drops for Dry Eye Disease
- InSite Vision Commences Phase 1/2 Clinical Study of ISV-303 for Post-Surgical Ocular Pain and Swelling Following Cataract and Other Surgeries
- Is BromSite More Effective Than Bromday Eye Drops For Postoperative Inflammation and Reduction of Ocular Pain?
- Acuvail™ From Allergan Receives FDA Approval for Post-Cataract Surgery Treatment
Jump down to form below to submit your own comments